385 related articles for article (PubMed ID: 24392842)
1. Targeting HMGB1 in the treatment of sepsis.
Wang H; Ward MF; Sama AE
Expert Opin Ther Targets; 2014 Mar; 18(3):257-68. PubMed ID: 24392842
[TBL] [Abstract][Full Text] [Related]
2. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.
Wang H; Ward MF; Sama AE
Shock; 2009 Oct; 32(4):348-57. PubMed ID: 19333143
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of HMGB1-targeting agents in sepsis.
Wang H; Zhu S; Zhou R; Li W; Sama AE
Expert Rev Mol Med; 2008 Nov; 10():e32. PubMed ID: 18980707
[TBL] [Abstract][Full Text] [Related]
4. HMGB1 as a therapeutic target for sepsis: it's all in the timing!
Gentile LF; Moldawer LL
Expert Opin Ther Targets; 2014 Mar; 18(3):243-5. PubMed ID: 24479494
[TBL] [Abstract][Full Text] [Related]
5. A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis.
Li J; Zhu CS; He L; Qiang X; Chen W; Wang H
Expert Opin Ther Targets; 2023; 27(7):575-591. PubMed ID: 37477229
[TBL] [Abstract][Full Text] [Related]
6. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.
Tamada K; Nakajima S; Ogawa N; Inada M; Shibasaki H; Sato A; Takasawa R; Yoshimori A; Suzuki Y; Watanabe N; Oyama T; Abe H; Inoue S; Abe T; Yokomizo T; Tanuma S
Biochem Biophys Res Commun; 2019 Apr; 511(3):665-670. PubMed ID: 30826057
[TBL] [Abstract][Full Text] [Related]
7. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
8. HMGB1 as a potential therapeutic target.
Wang H; Li W; Goldstein R; Tracey KJ; Sama AE
Novartis Found Symp; 2007; 280():73-85; discussion 85-91, 160-4. PubMed ID: 17380789
[TBL] [Abstract][Full Text] [Related]
9. Use of animal model of sepsis to evaluate novel herbal therapies.
Li W; Zhu S; Zhang Y; Li J; Sama AE; Wang P; Wang H
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22525208
[TBL] [Abstract][Full Text] [Related]
10. [Advances in high mobility group box-1 protein mediated multiple organ dysfunction and its potential interventional strategies].
Yao YM; Xu S; Sheng ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Aug; 29(4):459-65. PubMed ID: 19209785
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane Reduces HMGB1-Mediated Septic Responses and Improves Survival Rate in Septic Mice.
Lee IC; Kim DY; Bae JS
Am J Chin Med; 2017; 45(6):1253-1271. PubMed ID: 28830206
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis.
Parrish W; Ulloa L
Methods Mol Biol; 2007; 361():145-62. PubMed ID: 17172710
[TBL] [Abstract][Full Text] [Related]
13. Antiseptic effect of vicenin-2 and scolymoside from Cyclopia subternata (honeybush) in response to HMGB1 as a late sepsis mediator in vitro and in vivo.
Lee W; Yoon EK; Kim KM; Park DH; Bae JS
Can J Physiol Pharmacol; 2015 Aug; 93(8):709-20. PubMed ID: 26243020
[TBL] [Abstract][Full Text] [Related]
14. Reversing established sepsis with antagonists of endogenous high-mobility group box 1.
Yang H; Ochani M; Li J; Qiang X; Tanovic M; Harris HE; Susarla SM; Ulloa L; Wang H; DiRaimo R; Czura CJ; Wang H; Roth J; Warren HS; Fink MP; Fenton MJ; Andersson U; Tracey KJ
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):296-301. PubMed ID: 14695889
[TBL] [Abstract][Full Text] [Related]
15. Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review.
Zhu CS; Wang W; Qiang X; Chen W; Lan X; Li J; Wang H
Cells; 2021 Aug; 10(9):. PubMed ID: 34571869
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
Cho W; Koo JY; Park Y; Oh K; Lee S; Song JS; Bae MA; Lim D; Lee DS; Park SB
J Med Chem; 2017 Jan; 60(1):170-179. PubMed ID: 28001381
[TBL] [Abstract][Full Text] [Related]
17. Aloin Reduces HMGB1-Mediated Septic Responses and Improves Survival in Septic Mice by Activation of the SIRT1 and PI3K/Nrf2/HO-1 Signaling Axis.
Yang S; Lee W; Lee BS; Lee C; Park EK; Ku SK; Bae JS
Am J Chin Med; 2019; 47(3):613-633. PubMed ID: 30966773
[TBL] [Abstract][Full Text] [Related]
18. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
Czura CJ; Yang H; Tracey KJ
J Infect Dis; 2003 Jun; 187 Suppl 2():S391-6. PubMed ID: 12792856
[TBL] [Abstract][Full Text] [Related]
19. Suppressive Effects of Ginsenoside Rh1 on HMGB1-Mediated Septic Responses.
Lee W; Cho SH; Kim JE; Lee C; Lee JH; Baek MC; Song GY; Bae JS
Am J Chin Med; 2019; 47(1):119-133. PubMed ID: 30630344
[TBL] [Abstract][Full Text] [Related]
20. CBP Bromodomain Inhibition Rescues Mice From Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses.
Bi X; Jiang B; Zhou J; Fan X; Yan X; Liang J; Luo L; Yin Z
Front Immunol; 2020; 11():625542. PubMed ID: 33603756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
